SONG Xia 1,2,3,4 , LIU Zheng 2,3,4,5 , LIU Yan 1,2,3,4 , LI Siyu 2,3,4,5 , SHI Yuqing 1,2,3,4 , DIAO Sha 2,3,4 , LIU Dan 2,3,4 , ZOU Kun 2,3,4 , LU Runxin 2,3,4 , ZENG Linan 2,3,4 , ZHANG Aimin 6 , XIAO Hongjie 6 , ZHANG Lingli 2,3,4,7
  • 1. West China School of Pharmacy, Sichuan University, Chengdu 610041, P. R. China;
  • 2. Department of Pharmacy/Evidence-Based Pharmacy Center, West China Second University Hospital, Sichuan University; Children’s Medicine Key Laboratory of Sichuan Province, Chengdu 610041, P. R. China;
  • 3. NMPA Key Laboratory for Technical Research on Drug Products in vitro and in vivo Correlation, Chengdu 610041, P. R. China;
  • 4. Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu 610041, P. R. China;
  • 5. West China School of Medicine, Sichuan University, Chengdu 610041, P. R. China;
  • 6. Medical Instrument Management Center, National Health Commission of the People’s Republic of China, Beijing 100044, P. R. China;
  • 7. Chinese Evidence-based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
ZHANG Lingli, Email: zhanglingli@scu.edu.cn
Neoplasms; Guideline; Consensus; Essential medicines
10.7507/1672-2531.202408164
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective To compare the recommended medicines from malignancy guidelines/consensuses with essential medicines from the 2023 World Health Organization Model List of Essential Medicines (WHO-EML) and the 2018 National Essential Medicine List (NEML) in differences and similarities. Methods Ten guideline databases/association websites including Guidelines International Network, and the American Cancer Society, etc. were systematically searched until July 2023. The latest guidelines/consensuses for ten malignant tumors were screened, including lung cancer, liver cancer, stomach cancer, and other cancers. Recommended medicines were extracted from guidelines/consensuses and compared with WHO and Chinese essential medicines. Results A total of 163 guidelines/consensuses were included, extracting 244 recommended medicines, 12 categories, mainly antineoplastic and immunomodulating agents (190 medicines, 10 subcategories). For the 244 recommended medicines, 29.92% (73/244) were included in WHO-EML and 23.36% (57/244) were included in NEML, among which 45 medicines were included both in WHO-EML and NEML, 27 in WHO-EML only, 11 in NEML only, and 161 in neither. Conclusion The number of recommended medicines in WHO-EML/NEML for ten malignancies is low, and the number in NEML is even much lower than that in WHO-EML. When adjusting medicines for malignant tumors in NEML, reference can be made to specific guidelines/consensuses and WHO-EML to ensure timely inclusion of applicable medicines and strengthen the role of essential medicines in meeting basic medical needs and rational use.

Copyright © the editorial department of Chinese Journal of Evidence-Based Medicine of West China Medical Publisher. All rights reserved